Ironwood Pharma (IRWD) Linzess Update Incrementally Positive, But Not Likely to Impact Sales - Cowen

Cowen analyst Borisk Peaker weighed in on Ironwood Pharmaceuticals (NASDAQ: IRWD) after the company reported positive topline data from the Phase 3 trial of Linzess in 6-17 year-old patients with functional constipation.

"Detailed data was not reported, only statical significance on the primary and secondary endpoints," Peaker commented. "We view this as an incrementally positive data for IRWD, but don't anticipate a noticeable impact on sales. Anticipate full data at an upcoming medical meeting."

The analyst reiterated a Market Perform rating and $9.00 price target on IRWD.

For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.

Shares of Ironwood Pharmaceuticals closed at $10.88 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Infosys shares fall as fourth-quarter revenue misses views
• Rentokil Initial (RTO) PT Lowered to $35 at Oppenheimer